Myelin Damage: Consequences for Neurological Function

Myelin, the lipid-rich sheath surrounding axons, enables rapid saltatory conduction of action potentials. Its damage disrupts neural communication, causing diverse neurological deficits.

Pathophysiological Effects

  • Slowed/blocked conduction: Loss of saltatory conduction → continuous conduction along demyelinated segments → slower, energy-intensive, failure-prone.
  • Ectopic impulses: Demyelinated axons generate spontaneous discharges → paresthesias, pain, tonic spasms.
  • Axonal degeneration: Chronic demyelination → secondary axonal loss → permanent disability.

Clinical Manifestations by Location

  • CNS (optic nerve, brainstem, spinal cord, cerebrum): Vision loss (optic neuritis), diplopia, ataxia, weakness, sensory loss, bladder/bowel dysfunction, cognitive impairment, fatigue.
  • PNS (nerve roots, peripheral nerves): Ascending paralysis (GBS), distal numbness/weakness, areflexia, autonomic instability.

Major Demyelinating Disorders

  • Multiple sclerosis (MS): Autoimmune CNS demyelination; relapsing-remitting or progressive.
  • Neuromyelitis optica spectrum disorder (NMOSD): AQP4-IgG mediated; optic neuritis + transverse myelitis.
  • MOG antibody disease (MOGAD): MOG-IgG; ADEM, optic neuritis, myelitis.
  • Guillain-Barré syndrome (GBS): Post-infectious PNS demyelination (AIDP variant).
  • Chronic inflammatory demyelinating polyneuropathy (CIDP): Chronic progressive/relapsing PNS.
  • Leukodystrophies: Genetic myelin metabolism defects (e.g., metachromatic leukodystrophy, adrenoleukodystrophy).

Therapeutic Strategies

  • Acute: High-dose corticosteroids, IVIG, plasma exchange.
  • Disease-modifying (MS): DMTs (interferons, glatiramer, natalizumab, ocrelizumab, BTK inhibitors, S1P modulators).
  • Symptomatic: Baclofen (spasticity), gabapentin (neuropathic pain), dalfampridine (walking speed in MS).
  • Rehabilitation: PT, OT, cognitive rehab.

Brain & Nervous System - Related Articles